Decoding Chronic Lymphocytic Leukemia
6/13/2011
A paper published online on June 13 in the Journal of Experimental Medicine identifies new gene mutations in patients with chronic lymphocytic leukemia (CLL)-a disease often associated with lack of response to chemotherapy and poor overall survival...
Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor...
Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri. Adaptimmune is focused on the use of T-cell therapy to treat cancer, with the body's own machinery - the T lymphocyte -- a cell that is being used to target and destroy cancerous cells...
Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (Nasdaq: SGEN), announced today that data on ADCETRIS™ (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London...
New Data Show Renal Impairment Is Strong Predictor Of Early Death In Patients With PNH
6/13/2011
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes...
Researchers Present Final Data From Phase 2 Studies Of Soliris(R) (Eculizumab) In Patients With AHUS
6/13/2011
Alexion Pharmaceuticals, Inc...
Enzo Biochem Inc. (NYSE:ENZ), as part of its continuing program to offer novel molecular tests, announced that its Enzo Clinical Labs subsidiary has reached an agreement with IncellDx Inc. of Menlo Park, CA, for the rights to market a proprietary laboratory test...
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S...
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) , a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a study published in the Proceedings of the National Academy of Sciences demonstrated that hyperthermia can be a powerful tool to inhibit the ability of cancer cells to repair the DNA damage caused by radiation or chemotherapy...
Freshmedx Venture To Bring Life Saving Technology To Millions At Risk Of Lung Cancer In Japan
6/13/2011
Freshmedx today announced a joint venture that will bring life saving technology to over 62 million people in Japan who are at high risk of developing lung cancer. The Salt Lake City, Utah based medical device company has entered into an agreement with a prominent Japanese partnership to co-develop, market, distribute and sell its proprietary Computerized Bioconductance Test (CB Test) in Japan...